OppenheimerFunds’s United Therapeutics UTHR Stock Holding History

OppenheimerFunds’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$425K	Sell	3,617 -1,019	-22%	-$119K	﹤0.01%	1424
2018 Q4	$505K	Buy	4,636 +540	+13%	+$62.6K	﹤0.01%	1372
2018 Q3	$524K	Sell	4,096 -552	-12%	-$68.3K	﹤0.01%	1427
2018 Q2	$526K	Sell	4,648 -24	-0.5%	-$2.64K	﹤0.01%	1398
2018 Q1	$525K	Buy	4,672 +1,115	+31%	+$142K	﹤0.01%	1373
2017 Q4	$526K	Buy	3,557 +65	+2%	+$8.26K	﹤0.01%	1489
2017 Q3	$409K	Buy	3,492 +245	+8%	+$31.3K	﹤0.01%	1598
2017 Q2	$421K	Buy	3,247 +366	+13%	+$45.7K	﹤0.01%	1584
2017 Q1	$390K	Buy	2,881 +573	+25%	+$86.8K	﹤0.01%	1608
2016 Q4	$331K	Buy	2,308 +322	+16%	+$41.1K	﹤0.01%	1564
2016 Q3	$235K	Buy	1,986 +1	+0.1%	+$120	﹤0.01%	1589
2016 Q2	$210K	Buy	+1,985	New	+$221K	﹤0.01%	1604
2016 Q1	–	Sell	-1,444	Closed	-$226K	–	1739
2015 Q4	$226K	Buy	+1,444	New	+$210K	﹤0.01%	1620

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OppenheimerFunds's UTHR Position: Q1 2019 in Review

OppenheimerFunds reduced its United Therapeutics (UTHR) stake by 22% in Q1 2019, selling an estimated $119K and leaving 3,617 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

OppenheimerFunds first reported a position in UTHR in Q4 2015 and has held it in 13 quarters since. The position peaked at $526K in Q2 2018. 378 funds tracked by Wall St. Rank hold UTHR as of Q1 2019.

OppenheimerFunds held 3,617 shares of United Therapeutics worth $425K as of Q1 2019.
OppenheimerFunds sold 1,019 United Therapeutics shares in Q1 2019, an estimated $119K.
United Therapeutics made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1424 holding.
OppenheimerFunds first reported a position in United Therapeutics in Q4 2015 and has held it in 13 quarters since.
OppenheimerFunds's United Therapeutics position peaked at $526K in Q2 2018.
378 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.